Propel Bio Management, LLC Athira Pharma, Inc. Transaction History
Propel Bio Management, LLC
- $82.4 Billion
- Q2 2025
A detailed history of Propel Bio Management, LLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 1,492,792 shares of ATHA stock, worth $567,260. This represents 0.55% of its overall portfolio holdings.
Number of Shares
1,492,792
Previous 1,492,792
-0.0%
Holding current value
$567,260
Previous $425 Million
6.0%
% of portfolio
0.55%
Previous 0.49%
Shares
1 transactions
Others Institutions Holding ATHA
# of Institutions
58Shares Held
18.5MCall Options Held
24.1KPut Options Held
0-
Perceptive Advisors LLC New York, NY5.4MShares$2.05 Million0.07% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.23MShares$1.23 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.54MShares$584,4070.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$567,2600.03% of portfolio
-
Black Rock Inc. New York, NY676KShares$256,9720.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $14.4M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...